Akoustis Technologies Inc reports results for the quarter ended in December - Earnings Summary

Aktis Oncology

13/02/2024 14:32

* Akoustis Technologies Inc  AKTS.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
December, identical to the same quarter last year.  The mean
expectation of five analysts for the quarter was for a loss
of 18 cents per share. Wall Street expected results to range
from -20 cents to -16 cents per share.
    * Revenue rose 19.6% to $7.02 million from a year ago;
analysts
expected $6.99 million. 
    * Akoustis Technologies Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The company reported a quarterly loss of $15.71 million.
    * Akoustis Technologies Inc shares had fallen by 12.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Akoustis
Technologies Inc is $1.00 

This summary was machine generated from LSEG data February 13 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.18          -0.19          Missed
 Sep. 30 2023      -0.18          -0.26          Missed
 Jun. 30 2023      -0.17          -0.21          Missed
 Mar. 31 2023      -0.19          -0.20          Missed